CRL · 10-Q · 2026Q3 · Full report

Operating Expense Trends

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-11-04 · Importance 46 · Surprise 56

Unallocated corporate costs increased $73.2 million, or 38.8%, to $261.8 million for the nine months ended September 26, 2026, and rose to 8.8% of revenue from 6.2%. The increase primarily reflected higher acquisition, integration, and divestiture costs and professional services fees for enterprise-wide efficiency initiatives, partly offset by a $15.3 million Wilmington asset-sale gain. Third-quarter unallocated costs increased $11.0 million, or 17.2%, to $74.8 million, driven primarily by professional services fees and legal costs. DSA selling, general and administrative expense declined $66.9 million, or 36.8%, to $115.0 million for the nine-month period.